MKManfred Konrad

Manfred Konrad

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Manfred Konrad has a total of 41 co-authors. Here are the top co-authors by number of shared publications:

  • Arnon Lavie

    Department of Biochemistry and Molecular Genetics, University of Illinois at Chicago, Chicago, IL, USA

    5 shared publications
  • Christos S. Karamitros

    From the Enzyme Biochemistry Group, Max Planck Institute for Biophysical Chemistry, Göttingen D-37077, Germany

    4 shared publications
  • Christian Monnerjahn

    Max-Planck-Institute for Biophysical Chemistry, Research Group Enzyme Biochemistry, 37077 Göttingen, Germany

    2 shared publications
  • Oliver Spangenberg

    From the ‡Department of Molecular Genetics, Max Planck Institute for Biophysical Chemistry, Göttingen D-37070, Germany and the §Department of Biochemistry and Molecular Biology, University of Illinois at Chicago, Chicago, Illinois 60607

    2 shared publications
  • Ralf Brundiers

    Max-Planck-Institut für Biophysikalische Chemie, Abteilung Molekulare Genetik, Am Fassberg 11, D-37077 Göttingen, Germany

    2 shared publications
  • Roger Sidney Goody

    Department of Structural Biochemistry, Max Planck Institute of Molecular Physiology

    2 shared publications

Latest Publications

  • A designed equine herpes thymidine kinase (EHV4 TK) variant improves ganciclovir-induced cell-killing

    by Theresa McSorley, Stephan Ort, Christian Monnerjahn, Manfred Konrad


  • Ultra-high throughput detection of single cell β-galactosidase activity in droplets using micro-optical lens array

    by Jiseok Lim, Jérémy Vrignon, Philipp Gruner, Christos S. Karamitros, Manfred Konrad, Jean-Christophe Baret

    We demonstrate the use of a hybrid microfluidic-micro-optical system for the screening of enzymatic activity at the single cell level. Escherichia coli β-galactosidase activity is revealed by a fluorogenic assay in 100 pl droplets. Individual droplets containing cells are screened by measuring their fluorescence signal using a high-speed camera. The measurement is parallelized over 100 channels equipped with microlenses and analyzed by image processing. A reinjection rate of 1 ml of emulsion per minute was reached corresponding to more than 105 droplets per second, an analytical throughput larger than those obtained using flow cytometry.


  • Preserving Catalytic Activity and Enhancing Biochemical Stability of the Therapeutic Enzyme Asparaginase by Biocompatible Multilayered Polyelectrolyte Microcapsules

    by Christos S. Karamitros, Alexey M. Yashchenok, Helmuth Möhwald, Andre G. Skirtach, Manfred Konrad

    The present study focuses on the formation of microcapsules containing catalytically active l-asparaginase (L-ASNase), a protein drug of high value in antileukemic therapy. We make use of the layer-by-layer (LbL) technique to coat protein-loaded calcium carbonate (CaCO3) particles with two or three poly dextran/poly-l-arginine-based bilayers. To achieve high loading efficiency, the CaCO3 template was generated by coprecipitation with the enzyme. After assembly of the polymer shell, the CaCO3 core material was dissolved under mild conditions by dialysis against 20 mM EDTA. Biochemical stability of the encapsulated l-asparaginase was analyzed by treating the capsules with the proteases trypsin and thrombin, which are known to degrade and inactivate the enzyme during leukemia treatment, allowing us to test for resistance against proteolysis by physiologically relevant proteases through measurement of residual l-asparaginase activities. In addition, the thermal stability, the stability at the physiological temperature, and the long-term storage stability of the encapsulated enzyme were investigated. We show that encapsulation of l-asparaginase remarkably improves both proteolytic resistance and thermal inactivation at 37 °C, which could considerably prolong the enzyme’s in vivo half-life during application in acute lymphoblastic leukemia (ALL). Importantly, the use of low EDTA concentrations for the dissolution of CaCO3 by dialysis could be a general approach in cases where the activity of sensitive biomacromolecules is inhibited, or even irreversibly damaged, when standard protocols for fabrication of such LbL microcapsules are used. Encapsulated and free enzyme showed similar efficacies in driving leukemic cells to apoptosis.


  • Open Access

    Balance of human choline kinase isoforms is critical for cell cycle regulation

    by Jens Gruber, Wei Cun See Too, Mun Teng Wong, Arnon Lavie, Theresa McSorley, Manfred Konrad

    The enzyme choline kinase (CK), which catalyzes the phosphorylation of choline to phosphorylcholine in the presence of ATP, has an essential role in the biosynthesis of phosphatidylcholine, the major constituent of all mammalian cell membranes. CK is encoded by two separate genes expressing the three isoforms CKα1, CKα2 and CKβ that are active as homodimeric or heterodimeric species. Metabolic changes observed in various cancer cell lines and tumors have been associated with differential and marked up‐regulation of the CKα genes, and specific inhibition of CKα activity has been proposed as a potential anti‐cancer strategy. As a result, less attention has been given to CKβ and its interaction with CKα. With the aim of profiling the intracellular roles of CKα and CKβ, we used RNA interference (RNAi) as a molecular approach to down‐regulate the expression of CK in HeLa cells. Individual and simultaneous RNAi‐based silencing of the CK α and β isoforms was achieved using different combinations of knockdown strategies. Efficient knockdown was confirmed by immunodetection using our isoform‐specific antibodies and by quantitative real‐time PCR. Our analyses of the phenotypic consequences of CK depletion showed the expected lethal effect of CKα knockdown. However, CKβ‐ and CKα + CKβ‐silenced cells had no aberrant phenotype. Therefore, our results support the hypothesis that the balance of the α and β isoforms is critical for cancer cell survival. The suppression of the cancer cell killing effect of CKα silencing by simultaneous knockdown of both isoforms implies that a more effective CK‐based anti‐cancer strategy can be achieved by reducing cross‐reactivity with CKβ.


  • Open Access

    Structural requirements for calmodulin binding to membrane‐associated guanylate kinase homologs

    by Ingo Paarmann, Ming F. Lye, Arnon Lavie, Manfred Konrad

    Effector molecules such as calmodulin modulate the interactions of membrane‐associated guanylate kinase homologs (MAGUKs) and other scaffolding proteins of the membrane cytoskeleton by binding to the Src homology 3 (SH3) domain, the guanylate kinase (GK) domain, or the connecting HOOK region of MAGUKs. Using surface plasmon resonance, we studied the interaction of members of all four MAGUK subfamilies—synapse‐associated protein 97 (SAP97), calcium/calmodulin‐dependent serine protein kinase (CASK), membrane palmitoylated protein 2 (MPP2), and zona occludens (ZO) 1—and calmodulin to determine interaction affinities and localize the binding site. The SH3‐GK domains of the proteins and derivatives thereof were expressed in E. coli and purified. In all four proteins, high‐affinity calmodulin binding was identified. CASK was shown to contain a Ca2+‐dependent calmodulin binding site within the HOOK region, overlapping with a protein 4.1 binding site. In ZO1, a Ca2+‐dependent calmodulin binding site was detected within the GK domain. The equilibrium dissociation constants for MAGUK–calmodulin interaction were found to range from 50 nM to 180 nM. Sequence analyses suggest that binding sites for calmodulin have evolved independently in at least three subfamilies. For ZO1, pulldown of GST‐calmodulin was shown to occur in a calcium‐dependent manner; moreover, molecular modeling and sequence analyses predict conserved basic residues to be exposed on one side of a helix. Thus, calmodulin binding appears to be a common feature of MAGUKs, and Ca2+‐activated calmodulin may serve as a general regulator to affect the interactions of MAGUKs and various components of the cytoskeleton.


  • Mimicking phosphorylation of Ser‐74 on human deoxycytidine kinase selectively increases catalytic activity for dC and dC analogues

    by Theresa McSorley, Stephan Ort, Saugata Hazra, Arnon Lavie, Manfred Konrad

    Intracellular phosphorylation of dCK on Ser‐74 results in increased nucleoside kinase activity. We mimicked this phosphorylation by a Ser‐74‐Glu mutation in bacterially produced dCK and investigated kinetic parameters using various nucleoside substrates. The S74E mutation increases the k cat values 11‐fold for dC, and 3‐fold for the anti‐cancer analogues dFdC and AraC. In contrast, the rate is decreased for the purine substrates. In HEK293 cells, we found that by comparing transiently transfected dCK(S74E)‐GFP and wild‐type dCK‐GFP, mimicking the phosphorylation of Ser‐74 has no effect on cellular localisation. We note that phosphorylation may represent a mechanism to enhance the catalytic activity of the relatively slow dCK enzyme.


  • Open Access

    Expressing engineered thymidylate kinase variants in human cells to improve AZT phosphorylation and human immunodeficiency virus inhibition

    by Birgitta M. Wöhrl, Laurence Loubière, Ralf Brundiers, Roger S. Goody, David Klatzmann, Manfred Konrad

    The triphosphorylated form of the nucleoside analogue AZT (AZTTP) acts as a chain terminator during reverse transcription of the human immunodeficiency virus (HIV) genome. The bottleneck in the conversion of AZT to AZTTP is the phosphorylation of AZT monophosphate (AZTMP) by cellular thymidylate kinase. Human thymidylate kinase was engineered to exhibit highly improved activity for AZTMP to AZTDP conversion. It was demonstrated here that genetically modified human cells transiently expressing these enzyme variants show more than 10-fold higher intracellular concentrations of AZTDP and AZTTP. Stable clones expressing these enzymes appear to phosphorylate AZTMP less efficiently, but first experiments indicate they are still more potent in HIV inhibition than the parental cells. It was proposed that the concept of introducing into human cells a catalytically improved human enzyme, rather than an enzyme of viral, bacterial or yeast origin, may serve as a paradigm for ameliorating the metabolic activation of an established drug.


  • Modulated Nucleoside Kinases as Tools to Improve the Activation of Therapeutic Nucleoside Analogues

    by Christian Monnerjahn, Manfred Konrad

    The use of nucleoside analogues in anticancer and antiviral treatments is often impaired by the slow intracellular activation of these drugs. This problem can be addressed by the modulation of rate-limiting enzymes in the activation pathways of the nucleoside analogues. Therapeutic strategies based on the combination of optimized activating enzymes and established nucleoside drugs promise significant improvements to traditional chemotherapy.